Azora Therapeutics, Inc. (AZR NASDAQ) stock market data APIs
$3.795
-0.03(-0.8%)
as of November 10, 2026
Try our APIs with
free plan!
Azora Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis. Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, Inc. in March 2019. The company was incorporated in 2017 and is based in Encino, California.
Prev. Close
3.795
Open
3.7673
High
3.9918
Low
3.7614
52 wk Range
1.31-8.25
Market Cap
9 847 K
Shares Outstanding
2 626 K
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Azora Therapeutics, Inc. data using free add-ons & libraries
Get Azora Therapeutics, Inc. Fundamental Data
Azora Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: -20
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Azora Therapeutics, Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Azora Therapeutics, Inc. News
New
Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Azora Therapeutics, Inc LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (Nasdaq: AZR), a biopharmaceutical company developing treatments for serious inflammatory diseases, tod...
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Adial Pharmaceuticals, Inc. Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora's common stock to begin trading on Nasdaq unde...
Get Azora Therapeutics, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.